Creo Medical Group PLC First use of Speedboat in South Africa

TIDMCREO

Creo Medical Group PLC

13 September 2018

Creo Medical Group plc

First placement and use of Speedboat in South Africa

Seven upper GI tract patients successfully treated

Chepstow, Wales - 13 September 2018 - Creo Medical Group plc (AIM: CREO) ("Creo" or the "Company"), a medical device company focused on the emerging field of surgical endoscopy, today announces the successful first use of its Speedboat endoscopic advanced energy device in the upper gastrointestinal tract (GI) in seven patients in South Africa. This follows the appointment of the Company's South African sales and distribution partner, First Medical Company, in July 2018.

The upper GI procedures, which were performed by a leading South African gastrointestinal surgeon, included the use of Speedboat in the oesophagus, stomach and duodenum. Elisabeth Oltmanns, Head of Professional Education at Creo, observed the cases as they were performed and commented:

"It was a pleasure to watch as the techniques and training we have established through the Creo Medical Clinical Education Programme to focus on lower GI usage was pioneered with procedures adapted for use in the upper GI, opening up the beginning of a new chapter in the evolution of the platform and advanced devices for GI treatment."

Speedboat is the first device developed for use with Creo's CROMA generator, an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave for controlled coagulation. The Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths. Until now, the device has only been used in a clinical setting in the United Kingdom for lower gastrointestinal procedures.

Craig Gulliford, Creo's Chief Executive Officer, commented:

"This is a double first for Creo. The use of our lead product, Speedboat, in upper GI procedures and in a clinical setting outside of the UK is a key step in the commercialisation of our technology, validating both our technology and the quality of our Clinical Education Programme and further supports our belief that our devices, powered by our CROMA electrosurgical platform, can improve patient outcomes. We remain committed to advancing the emerging field of surgical endoscopy through our innovative, cutting-edge energy platform and the suite of minimally invasive GI devices under development."

Contacts

 
 Creo Medical:          Cenkos:                                   FTI Consulting: 
 Richard Rees           Stephen Keys/Mark Connelly (NOMAD)        Brett Pollard / Mo Noonan 
  [phone]    Michael Johnson / Russell Kerr (Sales)    [phone] 
                         [phone]                       [e-mail] 
 

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, www.creomedical.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRABLGDCIXBBGID

(END) Dow Jones Newswires

September 13, 2018 02:01 ET (06:01 GMT)